Lineage Cell Therapeutics Stock News

Lineage Cell Therapeutics' OpRegen is partnered with Genentech/Roche. In my view, this is their main value driver in GA dry AMD. Looking ahead, their GAlette Phase 2a trial is enrolling, which could further validate the rest of their portfolio's potential. LCTX's pipeline also has OPC1 for spinal cord injury. Its preclinical R&D includes ANP1, PNC1, RND1, and ILT1.

Lineage Cell Therapeutics, Inc. ( LCTX ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Ioana Hone - Director of Investor Relations Brian Culley - CEO, President & Director Jill Howe - CFO & Principal Financial and Accounting Officer Conference Call Participants William Wood - B. Riley Securities, Inc., Research Division Joseph Pantginis - H.C.

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today reported its third quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern...

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, following th...